Myelogenous Leukemia, Acute Clinical Trial
Official title:
An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open-label, Phase II, Two-stage, Study of Xantrene® (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Lead-in stage: up to 12 (up to 2 cohorts in a 3+3 dose escalation design) Efficacy stage: up to 17 (Simon 2-stage design 9+8) Study Objectives: - Confirm safety and tolerability of the combination regimen - Time to response with combination treatment - Overall survival The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence: - First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2 - Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes - Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours. One cycle will comprise daily IV infusion of the combination treatment course for 4 or 5 consecutive days and rest period to between Day 30 and Day 42, based on patient performance and disease status.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00374296 -
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02665065 -
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT00907517 -
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
|
Phase 1 | |
| Completed |
NCT01635296 -
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01773408 -
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01641250 -
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT00130702 -
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
|
Phase 2 |